**Background of TBC1D2 Antibody**
TBC1D2 (Tre-2/Bub2/Cdc16 domain family member 2), also known as ARMUS, is a Rab GTPase-activating protein (GAP) involved in regulating intracellular vesicle trafficking and signaling pathways. It contains an N-terminal phosphotyrosine-binding (PTB) domain and a C-terminal TBC domain, which confers GAP activity toward specific Rab proteins, notably Rab7 and Rab11. TBC1D2 plays a role in modulating endosomal sorting, lysosomal degradation, and receptor recycling, impacting processes like autophagy, cell migration, and growth factor signaling.
Antibodies targeting TBC1D2 are essential tools for studying its expression, localization, and function in cellular and disease contexts. They are widely used in techniques such as Western blotting, immunofluorescence, and immunohistochemistry to investigate TBC1D2's interaction with partners like RalBP1 or its role in pathways linked to cancer progression, metabolic disorders, and neurodegenerative diseases. Dysregulation of TBC1D2 has been implicated in tumor metastasis (via Rab7-dependent EGFR degradation) and insulin resistance (through GLUT4 trafficking), making its study clinically relevant. Commercial TBC1D2 antibodies are typically validated for specificity in human, mouse, or rat models, often with emphasis on distinguishing isoforms or phosphorylation states. Researchers rely on these reagents to explore TBC1D2's mechanistic contributions to cellular homeostasis and pathology.